Kinetic models towards an enhanced understanding of diverse ADC conjugation reactions.

antibody-drug conjugate (ADC) conjugation reaction cysteine-conjugates interchain disulfide kinetic model payload site-specific conjugation

Journal

Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513

Informations de publication

Date de publication:
2024
Historique:
received: 19 03 2024
accepted: 07 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

The conjugation reaction is the central step in the manufacturing process of antibody-drug conjugates (ADCs). This reaction generates a heterogeneous and complex mixture of differently conjugated sub-species depending on the chosen conjugation chemistry. The parametrization of the conjugation reaction through mechanistic kinetic models offers a chance to enhance valuable reaction knowledge and ensure process robustness. This study introduces a versatile modeling framework for the conjugation reaction of cysteine-conjugated ADC modalities-site-specific and interchain disulfide conjugation. Various conjugation kinetics involving different maleimide-functionalized payloads were performed, while controlled gradual payload feeding was employed to decelerate the conjugation, facilitating a more detailed investigation of the reaction mechanism. The kinetic data were analyzed with a reducing reversed phase (RP) chromatography method, that can readily be implemented for the accurate characterization of ADCs with diverse drug-to-antibody ratios, providing the conjugation trajectories of the single chains of the monoclonal antibody (mAb). Possible kinetic models for the conjugation mechanism were then developed and selected based on multiple criteria. When calibrating the established model to kinetics involving different payloads, conjugation rates were determined to be payload-specific. Further conclusions regarding the kinetic comparability across the two modalities could also be derived. One calibrated model was used for an exemplary

Identifiants

pubmed: 39070164
doi: 10.3389/fbioe.2024.1403644
pii: 1403644
pmc: PMC11274341
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1403644

Informations de copyright

Copyright © 2024 Weggen, Bean, Hui, Wendeler and Hubbuch.

Déclaration de conflit d'intérêts

Authors MW, RB and KH are employed by AstraZeneca and report stock ownership and/or stock options or interest in AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Jan Tobias Weggen (JT)

Institute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.

Ryan Bean (R)

Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States.

Kimberly Hui (K)

Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States.

Michaela Wendeler (M)

Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States.

Jürgen Hubbuch (J)

Institute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.

Classifications MeSH